Replies to post #33096 on Biotech Values

[RockRat]

My understanding is that the nearest term meeting with the FDA has only to do with the "approvable" formulations of Indiplon. These have little marketability, though NBIX could attempt to train their sales force with them. But even that would require the IR formulation to show hope of approval afterwards, since NBIX would have to rehire a salesforce. I don't know why folks are so excited unless my understanding is incorrect. I'm very tempted to short NBIX, since this item seems to be responsible for the price rise of late. It'll sell off on almost any news, is my guess. Now, when they meet the FDA regarding the "not aprrovable" IR formulation, that's when things will get interestng.

Anyone else?

Regards, RockRat